Tinlarebant Phase 3 Data Shows 20% qAF Reduction vs Placebo in Stargardt Disease
BLTE has more than doubled off its 52-week low of $59.12.
Summary
Belite Bio presented new secondary endpoint data from its Phase 3 DRAGON trial of tinlarebant in Stargardt disease at the ASRS meeting. The key finding: quantitative autofluorescence (qAF), a marker of toxic bisretinoid accumulation, remained stable to slightly decreased (~2%) in treated patients versus a ~20% increase in the placebo group at month 25. This reinforces the drug's mechanism of reducing disease-driving toxins and adds to the previously reported 35.7% reduction in retinal lesion growth. The data arrives as the company advances through FDA review following its completed NDA submission in June. With no approved therapies for STGD1, these consistent efficacy signals across primary and secondary endpoints strengthen the approval case. The oral presentation at a major retina conference also raises awareness among potential prescribers.
At the time of this announcement, BLTE was trading at $150.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $59.12 to $200.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.